Curis (NASDAQ:CRIS) Posts Quarterly Earnings Results, Hits Estimates

Curis (NASDAQ:CRISGet Rating) released its quarterly earnings results on Thursday. The biotechnology company reported ($0.17) earnings per share for the quarter, meeting the consensus estimate of ($0.17), RTT News reports. Curis had a negative net margin of 490.80% and a negative return on equity of 54.04%. During the same period in the previous year, the firm earned ($0.12) earnings per share.

Curis Stock Up 1.1 %

Shares of CRIS stock traded up $0.01 during trading on Friday, reaching $1.00. The company’s stock had a trading volume of 3,595,677 shares, compared to its average volume of 2,630,219. The business has a fifty day moving average price of $1.03 and a 200-day moving average price of $1.80. The company has a market cap of $91.65 million, a price-to-earnings ratio of -1.75 and a beta of 2.66. Curis has a one year low of $0.70 and a one year high of $9.04.

Institutional Trading of Curis

A number of institutional investors have recently made changes to their positions in the business. Dynamic Technology Lab Private Ltd lifted its position in shares of Curis by 40.2% in the first quarter. Dynamic Technology Lab Private Ltd now owns 40,700 shares of the biotechnology company’s stock worth $97,000 after purchasing an additional 11,660 shares in the last quarter. Swiss National Bank raised its position in Curis by 7.9% during the first quarter. Swiss National Bank now owns 162,500 shares of the biotechnology company’s stock worth $387,000 after acquiring an additional 11,900 shares in the last quarter. Engineers Gate Manager LP bought a new stake in Curis during the first quarter worth $32,000. Vanguard Group Inc. raised its position in Curis by 0.9% during the first quarter. Vanguard Group Inc. now owns 4,241,608 shares of the biotechnology company’s stock worth $10,095,000 after acquiring an additional 38,980 shares in the last quarter. Finally, PNC Financial Services Group Inc. bought a new stake in Curis during the first quarter worth $143,000. Institutional investors own 78.15% of the company’s stock.

Wall Street Analysts Forecast Growth

Separately, StockNews.com upgraded shares of Curis from a “sell” rating to a “hold” rating in a report on Thursday, May 12th.

Curis Company Profile

(Get Rating)

Curis, Inc, a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small molecule drug candidate, which is in a Phase 1/2 clinical trial for the treatment of non-hodgkin lymphomas, and acute myeloid leukemia and myelodysplastic syndromes; and CI-8993, a monoclonal antibody designed to antagonize the V-domain Ig suppressor of T cell activation.

Featured Articles

Earnings History for Curis (NASDAQ:CRIS)

Receive News & Ratings for Curis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Curis and related companies with MarketBeat.com's FREE daily email newsletter.